blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4457239

EP4457239 - ENGINEERED IMMUNE CELLS WITH ENHANCED POTENCY AND USES OF SAME IN IMMUNOTHERAPY [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  03.10.2024
Database last updated on 24.03.2026
FormerThe international publication has been made
Status updated on  28.07.2023
Most recent event   Tooltip29.11.2025New entry: Renewal fee paid 
Applicant(s)For all designated states
Nkarta, Inc.
1150 Veterans Boulevard
South San Francisco, CA 94080 / US
[2024/45]
Inventor(s)01 / TRAGER, James, Barnaby
San Francisco, California 94080 / US
02 / CHAN, Ivan
San Francisco, California 94080 / US
03 / WANG, Don-Hong
San Francisco, California 94080 / US
04 / LI, Guangnan
San Francisco, California 94080 / US
05 / LAZETIC, Alexandra, Leida, Liana
San Francisco, California 94080 / US
06 / GUO, Chao
San Francisco, California 94080 / US
 [2024/45]
Representative(s)Witte, Weller & Partner Patentanwälte mbB
Postfach 10 54 62
70047 Stuttgart / DE
[2024/45]
Application number, filing date23743886.618.01.2023
[2024/45]
WO2023US60850
Priority number, dateUS202263300978P19.01.2022         Original published format: US 202263300978 P
US202263366586P17.06.2022         Original published format: US 202263366586 P
[2024/45]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2023141472
Date:27.07.2023
Language:EN
[2023/30]
Type: A2 Application without search report 
No.:EP4457239
Date:06.11.2024
Language:EN
The application published by WIPO in one of the EPO official languages on 27.07.2023 takes the place of the publication of the European patent application.
[2024/45]
Search report(s)International search report - published on:US28.09.2023
(Supplementary) European search report - dispatched on:EP20.10.2025
ClassificationIPC:C07K14/725, C07K14/15, C07K19/00, C12N5/0783, C07K16/30, A61P35/00, A61K40/11, A61K40/31, A61K40/41, A61K40/42, C07K14/74, A61K40/15, A61K40/50
[2025/47]
CPC:
A61K40/11 (EP,US); A61K40/31 (EP,US); A61K40/15 (EP,US);
A61K40/416 (EP); A61K40/42 (EP,US); A61K40/50 (EP);
C07K14/7051 (EP,US); C07K14/70539 (EP); C07K16/30 (US);
C07K2319/02 (EP); C07K2319/03 (EP); C07K2319/43 (EP);
C07K2319/50 (EP) (-)
Former IPC [2024/45]C07K14/725, C07K14/15, C07K19/00, C12N5/0783, C07K16/30, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   ME,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2024/45]
TitleGerman:MANIPULIERTE IMMUNZELLEN MIT ERHÖHTER WIRKSAMKEIT UND VERWENDUNGEN DAVON IN DER IMMUNTHERAPIE[2024/45]
English:ENGINEERED IMMUNE CELLS WITH ENHANCED POTENCY AND USES OF SAME IN IMMUNOTHERAPY[2024/45]
French:CELLULES IMMUNITAIRES MODIFIÉES PRÉSENTANT UNE PUISSANCE AMÉLIORÉE ET LEURS UTILISATIONS EN IMMUNOTHÉRAPIE[2024/45]
Entry into regional phase30.07.2024National basic fee paid 
30.07.2024Search fee paid 
30.07.2024Designation fee(s) paid 
30.07.2024Examination fee paid 
Examination procedure30.07.2024Examination requested  [2024/45]
18.02.2025Amendment by applicant (claims and/or description)
Fees paidRenewal fee
19.12.2024Renewal fee patent year 03
28.11.2025Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A] WO2021251271  (TEIJIN LTD et al.) [A] 1-15 * the whole document *
 [PX] WO2022165233  (ALLOGENE THERAPEUTICS INC et al.) [PX] 1-2,4-9 * the whole document *
 [E] WO2024023802  (CRISPR THERAPEUTICS AG et al.) [E] 1-15 * the whole document *
 [E] WO2024023804  (CRISPR THERAPEUTICS AG et al.) [E] 1-15 * the whole document *
International search[Y] WO2021202832  (PROGENITOR LIFE SCIENCES et al.) [Y] 1-3, 5, 7, 8, 10, 11, 12, 15 -20 * pg 21 In 13-15, pg 22 In 7-8, claims 1, 5, 6, 11. *
 [Y] US2018155717  (VALAMEHR BAHRAM et al.) [Y] 1-3, 5, 7, 8, 10, 11, 12, 15-20 * claim 26 *
 [Y] US2020399343  (CHAPARRO RIGGERS JAVIER FERNANDO et al.) [Y] 15-17 * para [0013], [0084], claim 2. *
 [Y] US2021268028  (DEPIL STÉPHANE ANDRÉ et al.) [Y] 20 * SEQ ID NO: 37. *
 [Y]   ASHKENAZI AVRAHAM, FAINGOLD OMRI, SHAI YECHIEL: "HIV-1 fusion protein exerts complex immunosuppressive effects", TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 38, no. 7, 1 July 2013 (2013-07-01), AMSTERDAM, NL , pages 345 - 349, XP093096422, ISSN: 0968-0004, DOI: 10.1016/j.tibs.2013.04.003 [Y] 17 * . Especially abstract. *

DOI:   http://dx.doi.org/10.1016/j.tibs.2013.04.003
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.